Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo
Executive Summary
Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.
You may also be interested in...
Gilead Polymerase Inhibitor Demonstrates RVR In All ELECTRON Patients At Four Weeks
During its quarterly earnings call, Gilead gave the market a snippet of positive data for its hepatitis C candidate GS-7977, priming investors for the drug’s blockbuster potential.
Will Pharmasset’s $11 Billion Windfall Benefit Other HCV Players?
Gilead Sciences’ offer of $11 billion for Pharmasset shattered all previous records for the cost of buying out a clinical-stage biotech and further cemented the status of hepatitis C as one of the hottest spaces in biopharmaceutical development.
Clinical Stage Biotechs For Sale?
The oversized price tag attached to the recent acquisition of Pharmasset by Gilead has caused many to wonder how the take-out fits into historical patterns – or if it’s as big an outlier as it seems.